High Potential for the Immune and Antihypertensive Health Ingredients Market in Europe

The rising incidence of problems related to high blood pressure and weak immune system as well as the gravitation toward preventive healthcare is driving the European market for nutritional solutions in immune and antihypertensive health. The swine flu epidemic that hit Europe and the United States is one of the factors that boosted consumer interest in maintaining a healthy immune system.

Ingredients manufacturers in this space are cashing in on the growing awareness of the potential of immune health ingredients in preventing flu-like symptoms and respiratory infections. In particular, health ingredients that offer cholesterol- and blood pressure-lowering benefits are poised to pick up traction. Although blood pressure lowering ingredients are not currently very popular, they are expected to slowly catch up due to improving consumer awareness.

New analysis from Frost & Sullivan, European Market for Nutritional Solutions in Immune and Antihypertensive Health, finds that the market earned revenues of $577.9 million in 2009 and estimates this to reach $838.6 million in 2016.

"The sheer extent at which cardiovascular disease (CVD) affects the population in Europe, including those with hypertension, offers significant opportunities for ingredient manufacturers," says Frost & Sullivan Senior Research Analyst Sneha Pasricha.

However, the preference for traditional modes of lowering blood pressure such as exercise, weight management, salt reduction, and drugs such as diuretics, beta-blockers, angiotensive converting enzyme (ACE) inhibitors, calcium channel blockers or vasodilators is hindering market momentum.

Similarly, immune health ingredients segment is faced with the challenge of rigorous competition that is prevalent among the plethora of such ingredients available in the market. Most of these ingredients are positioned for other health benefits as well. For instance, probiotics and prebiotics are projected primarily as providers of digestive health benefits rather than positive immune health advantages. Such a scenario creates confusion in the minds of consumers and dissuades them from buying such ingredients.

"Besides, regulatory issues pertaining to health claims are limiting innovation and growth in the European Market for Nutritional Solutions in Immune and Antihypertensive Health, like any other health ingredient market in the region," notes Pasricha. "Health claim regulations in Europe are getting increasingly complex and vague with the Nutrition and Health Claims Regulation adopted in 2006."

Steps by European Food Safety Agency (EFSA) directed at bringing clarity on the criteria required for positive scientific opinion from the organisation with respect to health claims is likely to encourage innovation in the market.

"Manufacturers must make efforts to ramp up awareness levels among consumers about the scientific-backing and the mode of action of their immune and anti-hypertensive health ingredients," says Pasricha. "Proactive research initiatives by manufacturers supporting their ingredients efficacy, empowered with apt promotional efforts could prove instrumental in increasing consumer/customer trust and acceptance."

If you are interested in more information on this study, please send an e-mail with your contact details to Chiara Carella, Corporate Communications, at This email address is being protected from spambots. You need JavaScript enabled to view it..

European Market for Nutritional Solutions in Immune and Antihypertensive Health is part of the Chemicals & Materials Growth Partnership Service program, which also includes research in the following markets: Trends and Opportunities in the European Protein Ingredients Market, European Market for Enzymes in Food Application, European Digestive Ingredients in Animal Feed Market, and U.S. Digestive Ingredients in Animal Feed Market. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.